Trimipramine is an antidepressant belonging to the tricyclic class. It treats symptoms of depression by targeting chemicals in the brain. Trimipramine is not approved for use by patients under 18 years old.
Before using this drug, tell your doctor your medical history, especially if you’ve had a history of mental illness or psychosis, liver or heart disease, an overactive thyroid, a history of heart disease and stroke, glaucoma, diabetes, and urination problems. Inform your doctor if you become pregnant or breast-feed. Symptoms may take up to 4 weeks to improve. Alert your surgeon that you take trimipramine if you undergo surgery. Do not stop using suddenly.
Do not use trimipramine if you have used a MAO inhibitor in the past 14 days or if you’ve recently had a heart attack. Some young people report suicidal ideation when first starting an antidepressant. Don’t use trimipramine if you are allergic to other antidepressants like amitriptyline, amoxapine, and nortriptyline. Overdose can be fatal; symptoms include: vomiting, extreme drowsiness, fainting, and feeling cold. Avoid alcohol. Use caution when driving. Avoid sunlight and tanning bed exposure. If you take fluoxetine, you must wait 5 weeks before starting trimipramine.
Get emergency medical assistance if you suspect an overdose or allergic reaction. Inform your doctor of any new or worsening mood/behavior changes. Contact your doctor at once if you experience a serious effect such as: vision problems, lightheadedness, chest pain or pounding heart, confusion, seizure, difficulty urinating, easy bruising or unusual bleeding, sudden weakness, flu-like symptoms, restless muscles, and symptoms of excess serotonin. Other side effects include: blurred vision, insomnia, drowsiness, numbness and tingling, balance problems, nausea and vomiting, dry mouth, breast swelling in both sexes, and weight changes. Interactions may include: SSRI antidepressants used in the past 5 weeks, St. John’s wort, fentanyl and tramadol, cold medicine, heart rhythm medicine, migraine medicine, and more.